secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0000014272-24-000094
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers Squibb Q1 revenue up 5% to $11.9B; GAAP loss per share $5.89 on acquired IPRD charges
--------------------------------------------------------------------------------

- Q1 revenues $11,865M (+5% reported, +6% ex-FX); growth portfolio revenues $4,767M (+8%, +11% ex-FX).
- GAAP loss per share ($5.89); Non-GAAP loss per share ($4.40); includes $6.30/share impact from acquired IPRD and licensing.
- Completed acquisitions of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune collaboration.
- Announced strategic productivity initiative targeting ~$1.5B in cost savings, majority reinvested for innovation.
- Updated 2024 non-GAAP EPS and line-item guidance to reflect recent transactions; Abecma and Breyanzi received new U.S. approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427224000094/0000014272-24-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427224000094/bmy-20240425.htm
  HTML page:      https://secwatch.observer/filing/0000014272-24-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer